TraceLink Named to the 2025 RXinsider Pharmacy500 List for Excellence in Pharmacy Supply Chain Innovation

January 23, 2025 02:00 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

TraceLink recognized for advancing digitalization and orchestration in the pharmacy supply chain, ensuring safe and timely access to medications

BOSTON, Jan. 22, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, is honored to be named to the Pharmacy500 list for the second year in a row, recognizing 500 organizations that have made a significant impact on the U.S. pharmacy industry over the past year.

"As regulations like the Drug Supply Chain Security Act (DSCSA) reshape the industry, our focus remains on empowering our customers with transformative solutions that ensure compliance, enhance safety, and drive operational excellence," said Shabbir Dahod, President and CEO of TraceLink. "This recognition reflects the trust that our growing digital network community places in TraceLink to help navigate the complexities of the modern supply chain while delivering impactful results to patients."

TraceLink specializes in a comprehensive suite of platform services that address key challenges in the pharmaceutical industry, including DSCSA compliance, track-and-trace orchestration, pharmacy and supply chain inventory visibility, and targeted product recall identification. Furthermore, with the recent launch of OPUS, the Orchestration Platform for Universal Solutions, democratized access to end-to-end supply chain integration and orchestration is finally available for customers and trading partners that wish to propel their supply chain management function to new heights of innovation and efficiency.

Gregory Cianfarani, RPh, Founder and CEO of RXinsider, established the Pharmacy500 to honor companies and organizations that are making a meaningful impact on the pharmaceutical industry. According to Cianfarani, the award "celebrates those companies that are transforming the pharmacy landscape – whether by driving operational efficiencies or advancing exceptional patient care."

In 2024, TraceLink welcomed more than 75 new pharmacy logos to its network, bringing the total number of pharmacy customers to more than 410. This growth reflects a strong demand for TraceLink's innovative solutions, which are helping pharmacies streamline operations and ensure compliance in an increasingly complex regulatory environment. This impressive expansion showcases the widespread adoption of TraceLink's solutions, as customers in the pharmaceutical supply chain industry continue to turn to the platform to enhance efficiency and navigate the evolving regulatory landscape.

With the Magnum release of the OPUS platform earlier this year, TraceLink set a new standard for compliance, supply chain integrity, and process optimization. This milestone innovation solidified TraceLink's position as a leader in the industry, earning its well-deserved recognition among the top organizations driving transformation in the pharmacy supply chain.

To learn more about TraceLink solutions, visit: https://www.tracelink.com/.

About Rxinsider: 
Headquartered in West Warwick, Rhode Island, RXinsider is a pharmacist-founded marketing/communications (MARCOM) and market intelligence (INTEL) company focused on pharmacy operations and the companies supporting dispensing pharmacies. Through our publications, digital platforms, market research, and training resources, RXinsider educates pharmacy management and industry professionals on the products, services, and trends that impact pharmacy operations across the supply chain.

About TraceLink
TraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely. 

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.